Evolus (NASDAQ:EOLS) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Evolus (NASDAQ:EOLS) from a hold rating to a buy rating in a report published on Saturday morning.

Other analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. BTIG Research reaffirmed a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday, June 17th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Evolus Stock Up 2.4%

Shares of Evolus stock opened at $7.59 on Friday. Evolus has a 52 week low of $3.86 and a 52 week high of $7.95. The business’s fifty day simple moving average is $6.50 and its 200-day simple moving average is $5.54. The firm has a market cap of $501.32 million, a PE ratio of -14.60 and a beta of 1.35.

Hedge Funds Weigh In On Evolus

Hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC acquired a new stake in shares of Evolus in the 1st quarter valued at about $5,289,000. Potomac Capital Management Inc. acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $939,000. Pinnacle Associates Ltd. grew its position in shares of Evolus by 15.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 782,365 shares of the company’s stock worth $5,203,000 after acquiring an additional 107,490 shares during the last quarter. Rice Hall James & Associates LLC grew its position in shares of Evolus by 8.8% during the first quarter. Rice Hall James & Associates LLC now owns 1,254,819 shares of the company’s stock worth $5,157,000 after acquiring an additional 101,375 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in shares of Evolus in the 4th quarter valued at $545,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.